Tesaro, hit hard by recent trial woes, hunts buyers—again: report

Zejula
Tesaro, which markets PARP inhibitor Zejula, is reportedly seeking a buyer. (Tesaro)

Tesaro has reportedly tried to sell itself before, but to no avail. But its newly lowered share price may be sparking some new buyout interest.

The company has brought on financial advisers to help it weigh a sale after drawing attention from a potential suitor, Bloomberg reports, citing unnamed sources. Those advisers have started reaching out to other potential buyers, too.

A Tesaro spokesperson did not return a request for comment by press time.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

RELATED: Sanofi, Gilead said to be eyeing potential $10B deal for prime cancer target Tesaro

It’s not the first time the Waltham, Massachusetts-based drugmaker, which markets PARP inhibitor Zejula, has weighed a sale. Last summer, the company put itself up for grabs and reportedly generated interest from then-M&A-starved Sanofi and another party, which was rumored to be Gilead.  

This time, though, Tesaro’s recent stock-price woes may be fueling the fire. The company saw its shares hammered earlier this month when phase 1 data on an immuno-oncology combination underwhelmed investors. It’s also locked in an intensely competitive battle with PARP rivals Clovis Oncology and an AstraZeneca-Merck team, which market Rubraca and Lynparza, respectively.

And while both Sanofi and Gilead have since struck other sizable deals—Gilead nabbed CAR-T drug maker Kite for $11.9 billion, while Sanofi forked over $11.6 billion for hemophilia specialist Bioverativ—either could still find the prospect of swallowing Tesaro appealing, Wedbush Securities Inc. analyst David Nierengarten told Bloomberg.

“A company like Gilead that’s been expanding their oncology efforts would make a lot of sense, … but at these prices, it could be just about anyone with an oncology focus looking to get a product tucked into their portfolio,” he said, as quoted by the news service.

Suggested Articles

Troubled Allergan is taking steps to appease investors, including bringing in a big-name biotech exec for guidance. But not everyone is impressed.

Bayer and J&J agreed to pay $775 million to wrap up about 25,000 lawsuits claiming their Xarelto anticoagulant caused severe bleeding.

The Monsanto acquisition "was and is a good idea," says Bayer chief executive, even as the company lost phase 1 of the first bellwether Roundup trial.